Human Genome Sciences News

Human Genome Sciences, Inc. announced today that its presentation at the Leerink Swann 2012 Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com . A member of Human Genome Sciences' senior management team will present a corporate overview on Wednesday, February 15, 2012, at 3:00 PM Eastern time.

The clear frontrunner among investors has been the out-of-the-money March 9 strike, where close to 10,100 puts have been traded -- more than half of them at the bid price, pointing to seller-driven activity.

Some would argue that commercial stage biotechology investing is less risky than those in clinical development with no marketed products.

Human Genome Sciences, Inc. announced today that its presentation at the 14th Annual BIO CEO & Investor Conference will be webcast and may be accessed at www.hgsi.com . A member of Human Genome Sciences' senior management team will present a corporate overview on Tuesday, February 14, 2012, at 11:30 AM Eastern time.

The Deal : Oracle announced Thursday that it has entered into an agreement to acquire Taleo Corporation for $46.00 per share or approximately $1.9 billion, net of Taleo's cash and debt.

On CNBC's Fast Money , Guy Adami suggested that Human Genome Sciences is a buy. Human Genome Sciences gained 6.00% in the regular trading session today, and it added 3.06% in the after hours.

Former FrontPoint Partners LLC fund manager Joseph F. "Chip" Skowron, sentenced to five years in prison for an insider-trading scheme, says that Morgan Stanley isn't a victim of his crimes and doesn't deserve restitution.

Short sellers can give a quick and easy look into what the market is currently thinking about a stock - stocks seeing more shares shorted over time are being viewed more negatively, and vice-versa. To illustrate this, we ran a screen on the healthcare industry for stocks seeing the most significant increases in shares shorted month-over-month, ... (more)

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, biopharmaceutical company Human Genome Sciences the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Close to 5,500 puts were traded at the out-of-the-money February 8 strike -- almost all of them at the bid price, pointing to seller-fueled activity.

I believe that Transcept's Intermezzo is an important new drug for insomnia and will be a commercial success.

Biotech companies have been all the rage for a while now with people hankering after their shares.

Going by the Magic Formula criteria, none of these companies meets either standard, largely because biotech companies need to front a lot of capital in the beginning to make money in the long term.